Prevention of human papillomavirus (HPV) infection and cervical cancer in China: How does HPV vaccination bring about benefits to Chinese women?

BioScience Trends

Volumn 7, Issue 4, 2013, Pages 159-167

  Liu, Xiaoyan ^a,b   Feng, Aihua ^c   Cui, Yimeng ^a   Tobe, Ruoyan Gai ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Fourth People's Hospital of Jinan   (China)

Author keywords

Cervical cancer; China; Human papillomavirus (HPV); Screening; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CHINA; FEMALE; HUMAN; IMMUNOLOGY; PAPILLOMAVIRUS INFECTION; UTERINE CERVIX TUMOR;

CHINA; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84886259271     PISSN: 18817815     EISSN: 18817823     Source Type: Journal    
DOI: 10.5582/bst.2013.v7.4.159     Document Type: Article

References (60)

1. The World Health Organization. Comprehensive cervical cancer prevention and control: A healthier future for girls and women. The World Health Organization, Geneva, Swizerland, 2013.
2. Lowy DR, Solomon D, Hildesheim A, Schiller JT, Schiffman M. Human papillomavirus infection and the primary and secondary prevention of cervical cancer. Cancer. 2008; 113 (Suppl 7):1980-1993.
3. de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis. 2007; 7:453-459.
4. Merck & Co. Gardasil [Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant]. http://www.merck.com/product/usa/pi_ circulars/g/gardasil/gardasil_pi.pdf (accessed June 02, 2013).
5. GlaxoSmithKline. Cervarix [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant]. http:// us.gsk.com/products/assets/us_cervarix.pdf (accessed June 02, 2013).
6. Zhao FH, Lewkowitz AK, Hu SY, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: A pooled analysis of 17 populationbased studies. Int J Cancer. 2012; 131:2929-2938.
7. Li J, Kang LN, Qiao YL. Review of the cervical cancer disease burden in mainland China. Asian Pac J Cancer Prev. 2011; 12:1149-1153.
8. Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM. Human papillomavirus vaccine introduction-The first five years. Vaccine. 2012; 30(Suppl.):F139-148.
9. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Eng J Med. 2011; 365:1576-1585.
10. Kane MA, Serrano B, Sanjose S, Witter S. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012; 30(Suppl.):F192-200.
11. Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhatunewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ. Inclusion of the benefits of enhanced crossprotection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis. 2013; 13:75.
12. Annemans L, Remy V, Oyee J, Largeron N. Costeffectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics. 2009; 27:231-245.
13. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G. A costeffectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007; 4:165-175.
14. Szucs TD, Largeron N, Dedes KJ, Rafia R, Benard S. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening program in Switzerland. Curr Med Res Opin. 2008; 24:1473-1483.
15. Lee VJ, Tay SK, Teoh YL, Yok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health. 2011; 11:203.
16. Dee A, Howell F. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening program. Eur J Public Health. 2010; 20:213-219.
17. Kohli M, Lawrence D, Haig, J, Anonychuk A, Demarteau N. Modeling the impact of the difference in crossprotection data between a human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine and human papillomavirus (HPV)-6/11/16/18 vaccine in Canada. BMC Public Health. 2012; 12:872.
18. Anonychuk AM, Bauch CT, Merid MF, Van Kriekinge G, Demarteau. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health. 2009; 9:401.
19. Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health. 2012; 15:622-631.
20. Dasbach EJ, Insinga RP, Elbasha EH. The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK. BJOG. 2008; 115:947-956.
21. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening program: A cost-effectiveness analysis. Cost Eff Resour Alloc. 2008; 6:4.
22. Capri S, Gasparini R, Panatto D, Demarteau N. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecol Oncol. 2011; 121:514-521.
23. Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol. 2009; 112:370-376.
24. Damm O, Nocon M, Roll S, Vauth C, Willich S, Greiner W. Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors. GMS Health Technol Assess. 2009; 5:Doc04.
25. Schobert D, Remy V, Schoeffski O. Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model. Health Econ Rev. 2012; 2:19.
26. Bergeron C, Largeron N, McAllister R, Mathevet P, Remy V. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care. 2008; 24:10-19.
27. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003; 290:781-789.
28. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013; 208:385-393.
29. Dasbash EJ (b), Largeron N, Elbasha EH. Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model. Expert Rev Pharmacoecon Outcomes Res. 2008; 8:491-500.
30. Sander BB, Rebolj M, Valentiner-Branth P, Lynge E. Introduction of human papillomavirus vaccination in Nordic countries. Vaccine. 2012; 30:1425-1433.
31. Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, Taketani Y. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: A cost-effectiveness analysis. BJOG. 2012; 119:177-186.
32. Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010; 20:385-392.
33. Voko Z, Nagyjanosi L, Kalo Z. Cost-effectiveness of adding vaccination with AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. BMC Public Health. 2011; 12:924.
34. Dasbach EJ, Nagy L, Brandtmüller A, Elbasha EH. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary. J Med Econ. 2010; 13:110-118.
35. Reynales-Shigematru LM, Rodrigues ER, Lazcano-Ponce E. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico. Arch Med Res. 2009; 40:503-513.
36. Inshiga RP, Dasbash EJ, Elbasha EH, Piug A, Reynales- Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation. Vaccine. 2007; 26:128-139.
37. Centers for Disease Control and Prevention (CDC). Progress toward implementation of human papillomavirus vaccination-the Americas, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011; 60:1382-1384.
38. Vanni T, Mendes Luz P, Foss A, Mesa-Frias M, Legood R. Economic modeling assessment of the HPV quadrivalent vaccine in Brazil: A dynamic individual-based approach. Vaccine. 2012; 30:4866-4871.
39. Goldie SJ, Levin C, Mosqueira-Lovón NR, Ortendahl J, Kim J, O'Shea M, Diaz Sanchez M, Mendoza Araujo MA. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. Rev Panam Salud Publica. 2012; 32:426-434.
40. Diaz M, Kim JJ, Albero G, de Sanjosé S, Clifford G, Bosch FX, Goldie SJ. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. Br J Cancer. 2008; 99:230-238.
41. Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand. BJOG. 2012; 119:166-176.
42. Ezat WP, Aljunid S. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pac J Cancer Prev. 2010; 11:79-90.
43. De Vincenzo R, Ricci C, Conte C, Scambia G. HPV vaccine cross-protection: Highlights on additional clinical benefit. Gynecol Oncol. 2013. (doi: 10.1016/j.ygyno.2013.05.033)
44. The World Health Organization. Cervical cancer screening in developing countries: Report of a WHO consultation. The World Health Organization, Geneva, 2002.
45. Dong Z. The Guideline for Screening and Early Detection and Treatment of Cancer in China. Peking University Medical Press, Beijing, China, 2005.
46. Chen Q, Xie LX, Qing ZR, et al. Epidemiologic characterization of human papillomavirus infection in rural Chaozhou, Eastern Guandong Province of China. PLoS One. 2012; 7:e32149.
47. Chen W, Zhang X, Molijn A, et al. Human papillomavirus type-distribution in cervical cancer in China: The 167 importance of HPV 16 and 18. Cancer Causes Control. 2009; 20:1705-1713.
48. Li J, Mei J, Wang X, Hu L, Lin Y, Yang P. Human papillomavirus type-specific prevalence in women with cervical intraepithelial neoplasm in Western China. J Clin Microbiol. 2012; 50:1079-1081.
49. Zhang L, Wang Y, Peng M, She Q, Xiang Q, Chen Q, Liu Z, Zhang W, Tao N, Qiu L, Wu X. Prevalence and type distribution of high-risk human papillomavirus infections among women in Wufeng County, China. Arch Gynecol Obstet. 2012; 286: 695-699.
50. Lo KW, Wong YF, Chan MK, et al. Prevalence of human papillomavirus in cervical cancer: A multicenter study in China. Int J Cancer. 2002; 100:327-331.
51. Wu EQ, Liu B, Cui JF, et al. Prevalence of type-specific human papillomavirus and pap results in Chinese women: A multi-center, population-based cross-sectional study. Cancer Causes Control. 2013; 24:795-803.
52. Li R, Li Y, Radley D, Liu Y, Huang T, Sings HL, Zhang L, Wang W, Zhong X, Saah AJ. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blinded placebocontrolled trials in Chinese males and females. Vaccine. 2010; 30:4284-4291.
53. Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF, Legood R, Smith MA, Nickson C, Qiao YL. Prevention of cervical cancer in rural China: Evaluation of HPV vaccination and primary HPV screening strategies. Vaccine. 2011; 29:2487-2494.
54. Goldie SJ, Diaz M, Kim SY, Levin CE, Van Minh H, Kim JJ. Mathematical models of cervical cancer prevention in the Asia Pacific Region. Vaccine. 2008; 26(Suppl 12):M17-M29.
55. Goldie SJ, O'Shea M, Diaz M, Kim SY. Benefits, cost requirements and cost-effectiveness of the HPV 16, 18 vaccines for cervical cancer prevention in developing countries: Policy implications. Reprod Health Matters. 2008; 16:86-96.
56. Li J, Li LK, Ma JF, Wei LH, Niyazi M, Li CQ, Xu AD, Wang JB, Liang H, Belinson J, Qiao YL. Knowledge and attitudes about human papillomavirus and HPV vaccines among women living in metropolitan and rural regions of China. Vaccine. 2009; 27:1210-1215.
57. Zhao FH, Tiggelaar SM, Hu SY, et al. A multi-center survey of HPV knowledge and attitudes toward HPV vaccination among women, government officials and medical personnel in China. Asian Pac J Cancer Prev. 2012; 13:2369-2378.
58. Garland SM, Cuzick J, Domingo EJ, Goldie SJ, Kim YT, Konno R, Parkin DM, Qiao YL, Sankaranarayanan R, Stern PL, Tay SK, Bosch FX. Recommendations for cervical cancer prevention in Asia Pacific. Vaccine. 2008; 26(Suppl 12):M89-M98.
59. Hakim AA, Dinh TA. Worldwide impact of the human papillomavirus vaccine. Curr Treat Options Oncol. 2009; 10:44-53.
60. Shi JF, Qiao YL, Smith JS, Dondog B, Bao YP, Dai M, Clifford GM, Franceschi S. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. Vaccine. 2008; 26(Suppl 12):M53-M59.